AstraZeneca partner Pieris ends work on HER2 drug tested in combo with Eli Lilly, Seagen cancer meds
As Pieris Pharmaceuticals favors an AstraZeneca-partnered program in asthma, and because the mid-stage study is taking longer than expected, the biotech is deciding to end work on a HER2 drug.
The Boston biotech put out word Thursday that it’s ending the development of cinrebafusp alfa (PRS-343), which was in a Phase II study for certain HER2 gastric cancers. Earlier in its development, the 4-1BB/HER2 fusion protein drug ran into a partial clinical hold in its Phase I in the summer of 2020. Despite that, Eli Lilly came to the table a month later to contribute its ramucirumab (Cyramza) and paclitaxel for the Phase II study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.